Not a consumer health, food, cosmetic, clinical, or household product
Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)
Doctors typically monitor kidney function during therapy to ensure the treatment remains safe
Slowing down the speed at which food leaves the stomach after a meal
These findings are significant because they are the first to show that encapsulating an MVM supplement with liposomes can influence the pharmacokinetic (PK) profile of multiple vitamins and minerals present in the supplement, thereby impacting the availability of nutrients